An observational study in Alcohol Use Disorder (AUD), Alcohol Abuse and Drug Abuse, sponsored by The Hospital of Vestfold. Active, not recruiting at 4 sites in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by The Hospital of Vestfold · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Alcoholism with a site in Norway — 3 open to participants now, 4 under way, none of them phase 3. Alcoholism · Norway.
Among the 11 studies in Alcoholism with a site in Norway, this one is the only one that started in 2021, is one of 4 observational ones, and was the 9th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →3 of the 11 studies in Alcoholism with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 18+
University Hospital of North Norway · Sites in Norway
Ages 18–65
Helse Stavanger HF · Sites in Norway
Ages 21+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 120 is below the median of 150 across 183 observational studies indexed under Alcoholism.
Median enrollment 40 across the 7 interventional studies, 210 across the 4 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 6 most frequent:
The Hospital of Vestfold is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
The Hospital of Vestfold has 1 study filed under Alcoholism — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Alcoholism with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Harmful alcohol use is a global risk factor for disease, injuries and death. Research on treatment of Alcohol use disorders (AUDs) indicates that different treatment modalities are equally effective, but also that a large group of patients do not change their drinking pattern despite being in treatment. It is assumed that it is not random who benefits from treatment. Thirty to forty percent of outcome variance in treatment is probably explained by patient factors, and we need more knowledge on how different patient factors moderate treatment effects.
Further, clinicians also need more knowledge about selecting patients to different therapies. The present study will investigate how patient factors predict outcome in group treatment of AUDs, and what predicts positive treatment outcomes over time. The study is designed as a quasi-experimental, multi-centre, follow-up study. Patients will be included from Vestfold Hospital Trust, Borgestadklinikken, Blue Cross Clinic, Behandlingssenteret Eina, Blue Cross Clinic and A-senteret, Oslo, Church City Mission. The Project will provide more knowledge about patients seeking treatment for AUDs, and specifically how patient factors predict outcome in group treatment. These results will in turn lead to better selection of treatment modalities, and patients will receive a more effective treatment earlier on.
Main aims: 1) How do patient factors predict outcome in group treatment of alcohol use disorders (AUDs)? 2) Do positive treatment outcomes last over time? Specifically, do the following factors: a) psychiatric comorbidity b) severity of alcohol use pre-treatment c) personality disorders and d) cognitive impairments predict 1) completion of group treatment and 2) positive outcome after 1 year. As an additional aim, we will investigate if the Montreal Cognitive Assessment test (MoCa) is feasible as a brief screening instrument for mild cognitive impairments for AUD patients.
HYPOTHESES, AIMS AND OBJECTIVES
The general objective of the study is to increase the knowledge of addiction treatment, and how therapy can be made more effective, especially in the case of AUD. In particular, the project will study how patient characteristics interact with treatment and influence therapy outcome. The main research questions are:
The project has two main aims. The first primary aim is predictors of successful treatment completion operationalized as percentage of participation in therapeutic activities. The second primary aim is predictors for effect of group therapy one year after treatment termination. Primary outcome variable is alcohol and substance use reduction, measured with AUDIT and DUDIT. Secondary outcomes are symptom level measured with SCL-90 and quality of life measured with WHOQOL-bref. In addition, register data concerning use of health services after finishing treatment, and participation in working life, will be collected three years after treatment completion.
PROJECT METHODOLOGY
The present study is designed as a quasi-experimental, multi-centre study on treatment in ordinary clinical practice. The study will include at least 120 patients (approximately 40 participants pr. fall and spring-inclusion term). Four data collection sites are included in the study:
Participants in the study will be patients group treatment for a primary diagnosis of AUD. Treatment is administered in a time-limited format at all sites. The therapy format may vary to some degree, but is similar in overall structure and content. In this quasi-experimental study research is carried out in an ordinary clinical situation, and study attempts to investigate the complexity of clinical practice. As a result, the researchers do not have control over all of the variables, but the results will be more ecologically valid with a higher degree of generalizibility.
PROJECT ARRANGEMENTS, METHOD SELECTION AND ANALYSES
The study will use well-researched tools and methods, used in both research and ordinary clincial practice. The following information will be entered in the registry:
Patient pre-therapy background: Earlier treatment episodes and diagnoses, demographic variables (age, sex, education, marital status, economical situation) will be retrieved from participants' journal.
Screening pre-treatment:
Screening pre- and post-treatment, and after 1 and 3 years:
Screening post-treatment:
1) Treatment satisfaction: 10 questions about treatment satisfaction.
Register data:
In addition, after 3 years, register data from patient journals and from NAV will be collected concerning working status, economical benefits and if the patient have undergone more treatment.
ANALYSES
Both intention to treat and per protocol analyses will be carried out on all participants and those who complete the treatment and data collection, until the last point of assessment. Mixed methods analyses may be used to include patients with incomplete protocols.
The outcome measures will be subjected to regression analyses to test:
The study will seek to use hierarchical regression analyses transcending the single predictor domains by entering those measures from each domain that correlates highest with outcome and lowest with predictors from other domains. For the first analyses there are only one outcome measure (participation in group treatment). For the second set of analyses (function after one year) there are multiple outcome measures (drinking/substance abuse, symptom level, function and quality of life). Thus, we will seek to construct a gross overall composite outcome measure based on normative data from the tests used.
For non-continuous data (axis 1 diagnosis, gender and marital status) analyses of variance will be computed with group-characteristics as independent variable and outcome as dependent. It is reasonable to assume that patients with combinations of substance abuse profiles, symptom level, cognitive impairments and demographic factors may constitute specific groups (clusters) with different prognosis. Cluster analysis will be applied to unravel distinct combinations of factors associated with good or poor prognosis. As an experiment, one substance use measure, one symptom distress measure, one cognitive functioning measure and one or two demographic markers will be included in the analysis. Cluster analysis is merely an explorative method designed to uncover post-hoc empirical groups with combinations of features, but may discern individual patterns that will not be evident in analyses of group means.
STATISTICAL POWER
It is important that the planned number of participants is sufficiently large to answer the research questions. It is a quasi-experimental design in the sense that division into subgroups are determined by attributes of the participants not under complete control by the researchers. Regarding statistical power, the the following examples are computed: If it is expected that 35 % (n=42) of the participants have an axis 1 diagnosis of major depression and that this group will have somewhat over half a standard deviation (.55) higher score on AUDIT/DUDIT one year after completed treatment, this difference will be statistically significant on the five percent alpha-level if there are 41 and 76 persons in the two groups (depression vs. absence of depression), which will then be within the planned sample size. Continuous data will be analyzed with correlations and hierarchical regressions. Small effect sizes (Cohen's d: .30) will be statistically significant on the five percent level with 85 participants.
All patients between 18 and 90 years enrolled in treatment at one of the study sites, and who participates in group treatment. Inclusion criteria is a primary diagnosis of alcohol use disorders. Patients with comorbid psychiatric, illegal drug use, personality and cognitive deficits problems are not excluded from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Lack of primary AUD-diagnosis
Successful treatment completion
Operationalized as percentage of participation in therapeutic activities
Time frame: At treatment completion assessed up to 14 days
Change in alcohol consumption
Change in alcohol consumption after 1 year. Measured with Alcohol use disorders identification test (AUDIT) and one additional question of number of alcohol units consumed during the last week.
Time frame: Assessed 1 year after treatment completion
Change in alcohol consumption
Change in alcohol consumption after 3 years. Measured with Alcohol use disorders identification test (AUDIT), and one additional question of number of alcohol units consumed during the last week.
Time frame: Assessed 3 years after treatment completion
Change in psychological symptom level
Measured with a) Symptom check list 90-R (SCL-90-R), level of psychological distress measured with global severity index (GSI). Higher score means higher symptom level, and lower score indicates lower degree of psychological symptoms. b) Quality of life measured with World Health Organization Quality of Life brief (WHOQOL-bref), assessment of quality of life. Higher score indicates higher satisfaction in life and less psychological distress.
Time frame: 1 year after treatment completion
Change in psychological symptom level
Measured with a) Symptom check list 90-R (SCL-90-R), level of psychological distress measured with global severity index (GSI). Higher score means higher symptom level, and lower score indicates lower degree of psychological symptoms. b) Quality of life measured with World Health Organization Quality of Life brief (WHOQOL-bref). Assesses satisfaction with life and level of distress.
Time frame: 3 years after treatment completion
Participation in working life and use of health services
Register data concerning use of health services after finishing treatment, and participation in working life, will be collected
Time frame: Assessed 3 years after treatment completion
Predictors for successful outcome of group therapy
Do 1) Psychiatric comorbidity as measured with Symptom check list 90 (SCL-90R) 2) Severity of alcohol use before treatment, as measured with Alcohol use disorders identification test (AUDIT) 3) Personality functioning assessed with Severity indices of personality problems (SIPP-118) 4) Cognitive deficits, assessed with subtests from Wechsler Adult Intelligence Scale (WAIS-IV): Similarities, information, visual puzzles, block design and digit span, and subtests from Delis-Kaplan Executive Function System (D-KEFS): Color Word Interference Test and tasks 2-4 from the Trail Making Test predict successful outcome one year after treatment completion.
Time frame: 1 year after treatment completion
Is Montreal Cognitive Assessment (MoCa) feasible as a brief screening instrument for mild cognitive impairments in patients with Alcohol use disorders (AUDs)
Scores from the MoCa-test will be compared with scores from Wechsler Adult Intelligence Scale (WAIS-IV): Similarities, information, visual puzzles, block design and digit span, and Delis-Kaplan Executive Function System (D-KEFS): Color Word Interference Test and tasks 2-4 from the Trail Making Test.
Time frame: 3 years after study start, when recruitment is completed
PDFs hosted by the registry, ClinicalTrials.gov.
Started Feb 2021 (actual). Primary completion is estimated for Jan 2026, 59 months after the start.
Of 74 non-industry observational studies under Alcoholism, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 65. This study's planned 59 months is above that.
Counting every sponsor, half of 76 studies reached it within 40 months; a quarter within 21 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital of Vestfold